# The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

> **NCT04372615** · PHASE2 · RECRUITING · sponsor: **University of Utah** · enrollment: 116 (estimated)

## Conditions studied

- Autoimmune Encephalitis
- Encephalitis

## Interventions

- **DRUG:** Inebilizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04372615
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-30
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04372615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04372615, "The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04372615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*